This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Karyopharm Starts Dosing With Selinexor for Coronavirus Infection
by Zacks Equity Research
Karyopharm (KPTI) doses the first patient in a phase II study evaluating the low dose of its drug Xpovio (selinexor) to treat hospitalized patients with severe COVID-19 infection. Shares up.
RedHill's Oncology Candidate to be Tested for Coronavirus
by Zacks Equity Research
RedHill (RDHL) inks a deal with NIAID for non-clinical testing of its investigational candidate RHB-107 to evaluate its activity against COVID-19. Stock up.
A Q1 Earnings Primer: Global Week Ahead
by John Blank
The coming wave of Q1 earnings releases will be parsed for fresher signals of economic activity -- including forward guidance -- than tends to be available from conventional macro releases.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly
Gilead Increases Enrollment Target, Pharma Rally Continues
by Ritujay Ghosh
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
5 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.
Roche's New Test to Detect Antibodies to Fight Coronavirus
by Zacks Equity Research
Roche (RHHBY) develops Elecsys, a new serology test, for the detection of antibodies against SARS-CoV-2, the virus causing COVID-19. The company plans to launch the same early next month.
Sanofi/Luminostics to Make Self-Testing Solution for Coronavirus
by Zacks Equity Research
Sanofi (SNY) partners with Luminostics to make a COVID-19 smartphone-based self-testing solution, which will be based on the latter's proprietary technology.
Moderna Rallies on US Government Grant for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) gets a commitment of up to $483 million from the U.S. Government Agency BARDA to accelerate the development of its mRNA-based coronavirus vaccine.
Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts
by Kinjel Shah
J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines
Can Contact-Tracing Apps Bring the Lockdown to a Close?
by Manaswita Ghosh Dutta
Major tech giants join forces to introduce mobile contact-tracing applications in a bid to resume normalcy in life amid the pandemic.
Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results
by Nalak Das
The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.
Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D
by Ritujay Ghosh
Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.
CytoDyn's Leronlimab Progressing Well in Coronavirus Program
by Zacks Equity Research
CytoDyn (CYDY) treats first patient in a phase IIb/III study evaluating leronlimab in severe and critically ill COVID-19 patients. A phase II study on leronlimab shows encouraging results in mild-to-moderate COVID-19 patients.
Gilead Down on Suspension of Coronavirus Study in China
by Zacks Equity Research
Gilead (GILD) declines after a study on investigational antiviral, remdesivir, was suspended in China due to the lack of eligible patients.
Top Research Reports for Comcast, Bristol-Myers & Walgreens
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), Bristol-Myers Squibb (BMY) and Walgreens Boots Alliance (WBA).
Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis
by Zacks Equity Research
The FDA confers a Fast Track status on Alnylam's (ALNY) RNAi therapeutic vutrisiran for treating adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Sanofi and Glaxo Collaborate to Develop Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) and Glaxo are contributing their proven technologies to develop a coronavirus vaccine, which may be manufactured at large scale.
Pharma Q1 Earnings Begin With J&J's Report: 3 Stocks to Buy
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.
Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up
by Ritujay Ghosh
If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure
by Sweta Jaiswal, FRM
Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.
SNY vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
Pfizer (PFE) Progressing Well With its Coronavirus Program
by Zacks Equity Research
Pfizer (PFE) is developing a vaccine as well as other treatment options targeting coronavirus infection, COVID-19. However, all developments are in pre-clinical stages.
Lilly Announces Clinical Study Plans for Coronavirus Disease
by Zacks Equity Research
Lilly (LLY) plans to develop its RA drug, Olumiant, as well as a pipeline candidate as potential treatments for COVID-19. Clinical studies are expected to begin this month.
Gilead Reports Promising Data on Experimental Coronavirus Drug
by Zacks Equity Research
Gilead (GILD) reports encouraging data on investigational antiviral, remdesivir, in patients hospitalized with COVID-19.